Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. Barr PM, et al. Among authors: friedberg jw. Blood. 2014 Aug 21;124(8):1259-65. doi: 10.1182/blood-2014-04-570044. Epub 2014 Jul 11. Blood. 2014. PMID: 25016003 Free PMC article. Clinical Trial.
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.
Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Friedberg JW, et al. Blood. 2005 Jan 15;105(2):489-95. doi: 10.1182/blood-2004-06-2156. Epub 2004 Sep 9. Blood. 2005. PMID: 15358617 Free article. Clinical Trial.
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH. Phillips GL, et al. Among authors: friedberg jw. Semin Oncol. 2004 Dec;31(6 Suppl 18):59-61. doi: 10.1053/j.seminoncol.2004.12.014. Semin Oncol. 2004. PMID: 15726525 Clinical Trial.
Diffuse large B-cell NHL.
Friedberg JW, Fisher RI. Friedberg JW, et al. Cancer Treat Res. 2006;131:121-40. doi: 10.1007/978-0-387-29346-2_4. Cancer Treat Res. 2006. PMID: 16704168 Review. No abstract available.
Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.
Schaefer-Cutillo J, Friedberg JW, Fisher RI. Schaefer-Cutillo J, et al. Among authors: friedberg jw. Oncology (Williston Park). 2007 Feb;21(2):203-12; discussion 214, 217, 221. Oncology (Williston Park). 2007. PMID: 17396483 Free article. Review.
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. Leonard JP, et al. Among authors: friedberg jw. Ann Oncol. 2007 Jul;18(7):1216-23. doi: 10.1093/annonc/mdm114. Epub 2007 Apr 29. Ann Oncol. 2007. PMID: 17470451 Free article. Clinical Trial.
321 results